

Date: November 06, 2025

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001

BSE Scrip Code: 544319

To, Sr. General Manager Listing Department **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Audio recordings of Earnings Conference Call for the quarter and half year ended September 30, 2025 pursuant to Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In compliance with Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company had Earnings Conference Call with several Analysts/Institutional Investors/Funds and other investors on the Un-audited Financial Results of the Company, for the quarter and half year ended September 30, 2025 ("Financial Results") on November 06, 2025. Mr. Sanjay Majmudar, Chairman, Mr. Swapnil Shah, Managing Director and Mr. Deval Shah, Whole Time Director and Chief Financial Officer (CFO) of the Company, represented the Company at the said Earnings Conference Call.

The audio recording of said Earnings Conference Call of the Company held today i.e. Thursday, November 06, 2025 is available on the website of the Company and can be accessed at the weblink: https://senorespharma.com/investor-meet/.

No Unpublished Price Sensitive Information was shared/discussed by the Company during the Earnings Conference Call.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra

Company Secretary and Compliance Officer ICSI Membership No.: F11464

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India